CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). by Anjan Debnath, Claudia M Calvet, Gareth Jennings, Wenxu Zhou, Alexander Aksenov, Madeline R Luth, Ruben Abagyan, W David Nes, James H McKerrow, Larissa M Podust

Get full text

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. by Shamila S Gunatilleke, Claudia M Calvet, Jonathan B Johnston, Chiung-Kuang Chen, Grigori Erenburg, Jiri Gut, Juan C Engel, Kenny K H Ang, Joseph Mulvaney, Steven Chen, Michelle R Arkin, James H McKerrow, Larissa M Podust

Get full text

Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target by Jonathan W. Choy, Clifford Bryant, Claudia M. Calvet, Patricia S. Doyle, Shamila S. Gunatilleke, Siegfried S. F. Leung, Kenny K. H. Ang, Steven Chen, Jiri Gut, Juan A. Oses-Prieto, Jonathan B. Johnston, Michelle R. Arkin, Alma L. Burlingame, Jack Taunton, Matthew P. Jacobson, James M. McKerrow, Larissa M. Podust, Adam R. Renslo

Get full text